<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543890</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-2018-129</org_study_id>
    <nct_id>NCT04543890</nct_id>
  </id_info>
  <brief_title>A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC</brief_title>
  <acronym>CTV</acronym>
  <official_title>A Multicenter, Prospective, Randomized Study Comparing Hypofractionated Radiotherapy With Hyperfractionated Radiotherapy Combined With Concurrent Chemotherapy and Omitting Clinical Target Volumes of the Primary Tumor in Limited-stage SCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For most of the patients with limited-stage SCLC, thoracic radiotherapy combined with&#xD;
      chemotherapy is the standard treatment at present. However, the optimal dose / fraction of&#xD;
      thoracic radiotherapy for limited-stage SCLC is still in controversial.This study is designed&#xD;
      as a prospecitive randomized non-inferiority trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>PFS, defined as the time from the date of randomization to the first date of documented objective progression disease or of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>OS, measured from the date of randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Small Cell Lung Cancer Limited Stage</condition>
  <arm_group>
    <arm_group_label>Hyperfrationated Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofrationated Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/15 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hyperfractionated radiotherapy</intervention_name>
    <description>Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).</description>
    <arm_group_label>Hyperfrationated Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiotherapy</intervention_name>
    <description>Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).</description>
    <arm_group_label>Hypofrationated Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.</description>
    <arm_group_label>Hyperfrationated Arm</arm_group_label>
    <arm_group_label>Hypofrationated Arm</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.</description>
    <arm_group_label>Hyperfrationated Arm</arm_group_label>
    <arm_group_label>Hypofrationated Arm</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically/cytologically confirmed diagnosis of SCLC.&#xD;
&#xD;
          2. Radiologically (including brain CT/MRI, chest and abdomen contrasted CT and bone&#xD;
             scintigraphy. PET/CT is recommended) confirmed limited-stage.&#xD;
&#xD;
          3. Patients should be between 18 and 75 years old.&#xD;
&#xD;
          4. ECOG performance status of 0-1 (Karnofsky performance status â‰¥ 80).&#xD;
&#xD;
          5. With adequate cardiac, pulmonary, bone marrow, hepatic and renal function.&#xD;
&#xD;
          6. With weight loss no more than 10% within 6 months before diagnosis.&#xD;
&#xD;
          7. Informed consent must be signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histology confirmed the mixed NSCLC components;&#xD;
&#xD;
          2. Other primary malignant tumors appeared within 5 years before the first administration&#xD;
             of the study drug, except for locally curable malignant tumors after radical treatment&#xD;
             (such as basal or squamous cell skin cancer, superficial bladder cancer or prostate,&#xD;
             cervical or breast carcinoma in situ, etc.);&#xD;
&#xD;
          3. Any disease or condition contraindicated by radiotherapy or chemotherapy;&#xD;
&#xD;
          4. Malignant pleural effusion and pericardial effusion;&#xD;
&#xD;
          5. Pregnant and lactating women;&#xD;
&#xD;
          6. The investigator believes that the subject's complications or other circumstances may&#xD;
             affect the compliance with the protocol or may not be suitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Chen, MD, PhD</last_name>
    <phone>+86-571-88122199</phone>
    <email>chenming@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chen, MD, PhD</last_name>
      <phone>+86-571-88122199</phone>
      <email>chenming@zjcc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiation dose</keyword>
  <keyword>radiotherapy target volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

